The filling of sterile drugs into the appropriate primary containers (in this case, prefilled syringes) is one of the most crucial steps in the entire production process.
According to experts in the healthcare industry, one in three adults are estimated to be suffering from some type of chronic clinical condition, such as multiple sclerosis, diabetes, rheumatoid arthritis and cardiovascular diseases.
Prefilled syringes were first launched in the 1970s and since then have undergone considerable changes.
Prefilled syringes have been in market for over two decades now and have witness significant growth in terms of both adoption and revenues.
The first successful use of prefilled syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins, in Europe.
RNA interference is a post transcriptional gene silencing process that is believed to have the potential to treat undruggable diseases.
Drug developers heavily rely on a number of broadcasting channels, which include direct to consumer (DTC) advertisements, product websites and conferences, to promote their proprietary drugs.
Over the years, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to further their R&D efforts related to the development of RNAi therapeutics.
In the recent past, several companies have collaborated with other industry players / research institutes to develop novel RNAi based products.